210 related articles for article (PubMed ID: 31093341)
21. Targeting human EGFR 2 (HER2) in salivary gland carcinoma.
Wotman M; El-Naggar A; Ferrarotto R
Expert Rev Anticancer Ther; 2023 Jun; 23(6):573-582. PubMed ID: 37114470
[TBL] [Abstract][Full Text] [Related]
22. A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomas.
Lee J; Park S; Jung HA; Lee SH; Seo S; Kim SB; Kim JW; Lee KW; Kang EJ; Kim JW; Choi YJ; Shim BY; An HJ; Park LC; Shin SH; Kim JJ; Oh SY; Kim MK; Ahn MJ
Cancer; 2023 Oct; 129(19):2966-2974. PubMed ID: 37246414
[TBL] [Abstract][Full Text] [Related]
23. A New Era in Salivary Gland Carcinoma Treatment: A Case Report.
Mendonça JC; Barbosa A; Vieira C; Dinis J
Cureus; 2023 Aug; 15(8):e42983. PubMed ID: 37671202
[TBL] [Abstract][Full Text] [Related]
24. Cancers of the Major Salivary Gland.
Son E; Panwar A; Mosher CH; Lydiatt D
J Oncol Pract; 2018 Feb; 14(2):99-108. PubMed ID: 29436307
[TBL] [Abstract][Full Text] [Related]
25. The efficacy of iodine-125 permanent brachytherapy versus intensity-modulated radiation for inoperable salivary gland malignancies: study protocol of a randomised controlled trial.
Liu SM; Wang HB; Sun Y; Shi Y; Zhang J; Huang MW; Zheng L; Lv XM; Zheng BM; Reilly KH; Yan XY; Ji P; Wu YF; Zhang JG
BMC Cancer; 2016 Mar; 16():193. PubMed ID: 26951097
[TBL] [Abstract][Full Text] [Related]
26. [Prognostic value of immunohistochemistry in salivary gland cancer].
Ettl T; Schwarz S; Kühnel T; Stockmann P; Reichert TE; Driemel O
HNO; 2008 Feb; 56(2):231-8. PubMed ID: 18214402
[TBL] [Abstract][Full Text] [Related]
27. Trastuzumab for Her2/neu-positive metastatic salivary gland carcinoma: Case report and review of the literature.
Firwana B; Atassi B; Hasan R; Hasan N; Sukari A
Avicenna J Med; 2012 Jul; 2(3):71-73. PubMed ID: 23826550
[TBL] [Abstract][Full Text] [Related]
28. First experiences with
Klein Nulent TJW; van Es RJJ; Willems SM; Braat AJAT; Devriese LA; de Bree R; de Keizer B
EJNMMI Res; 2021 Dec; 11(1):126. PubMed ID: 34905121
[TBL] [Abstract][Full Text] [Related]
29. Systemic therapies for salivary gland adenoid cystic carcinoma.
Sahara S; Herzog AE; Nör JE
Am J Cancer Res; 2021; 11(9):4092-4110. PubMed ID: 34659878
[TBL] [Abstract][Full Text] [Related]
30. First Line Androgen Deprivation Therapy vs. Chemotherapy for Patients With Androgen Receptor Positive Recurrent or Metastatic Salivary Gland Carcinoma-A Retrospective Study.
Viscuse PV; Price KA; Garcia JJ; Schembri-Wismayer DJ; Chintakuntlawar AV
Front Oncol; 2019; 9():701. PubMed ID: 31428578
[No Abstract] [Full Text] [Related]
31. Chemoreirradiation for recurrent salivary gland malignancies.
Pederson AW; Haraf DJ; Blair EA; Stenson KM; Witt ME; Vokes EE; Salama JK
Radiother Oncol; 2010 Jun; 95(3):308-11. PubMed ID: 20385414
[TBL] [Abstract][Full Text] [Related]
32. Recent advances in the treatment of salivary gland cancers: emphasis on molecular targeted therapy.
Milano A; Longo F; Basile M; Iaffaioli RV; Caponigro F
Oral Oncol; 2007 Sep; 43(8):729-34. PubMed ID: 17350323
[TBL] [Abstract][Full Text] [Related]
33. New approaches in salivary gland carcinoma.
Even C; Baste N; Classe M
Curr Opin Oncol; 2019 May; 31(3):169-174. PubMed ID: 30844885
[TBL] [Abstract][Full Text] [Related]
34. Systemic therapy in metastatic salivary gland carcinomas: A pathology-driven paradigm?
Alfieri S; Granata R; Bergamini C; Resteghini C; Bossi P; Licitra LF; Locati LD
Oral Oncol; 2017 Mar; 66():58-63. PubMed ID: 28249649
[TBL] [Abstract][Full Text] [Related]
35. Adoption of adjuvant chemotherapy in high-risk salivary gland malignancies.
Gordon AJ; Chow MS; Patel A; Hu KS; Li Z; Jacobson AS; Vaezi AE; Tam MM; Givi B
Head Neck; 2023 Jan; 45(1):167-177. PubMed ID: 36245302
[TBL] [Abstract][Full Text] [Related]
36. Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study.
Kurzrock R; Bowles DW; Kang H; Meric-Bernstam F; Hainsworth J; Spigel DR; Bose R; Burris H; Sweeney CJ; Beattie MS; Blotner S; Schulze K; Cuchelkar V; Swanton C
Ann Oncol; 2020 Mar; 31(3):412-421. PubMed ID: 32067683
[TBL] [Abstract][Full Text] [Related]
37. Advances and challenges in precision medicine in salivary gland cancer.
Lassche G; van Boxtel W; Ligtenberg MJL; van Engen-van Grunsven ACH; van Herpen CML
Cancer Treat Rev; 2019 Nov; 80():101906. PubMed ID: 31644971
[TBL] [Abstract][Full Text] [Related]
38. Phase II trial of eribulin mesylate in recurrent or metastatic salivary gland malignancies.
Rodriguez CP; Martins RG; Baik C; Chow LQ; Santana-Davila R; Goulart BH; Lee S; Eaton KD
Head Neck; 2018 Mar; 40(3):584-589. PubMed ID: 29283469
[TBL] [Abstract][Full Text] [Related]
39. [The expression assessment of the estrogen, progesterone and HER2 receptors in selected malignant tumors of the salivary glands].
Golusiński W; Wegner A; Trzeciak P; Golusiński P; Sówka M; Kopczyński A; Bromboszcz M; Marszałek A
Otolaryngol Pol; 2013; 67(5):245-51. PubMed ID: 24021827
[TBL] [Abstract][Full Text] [Related]
40. Concurrent chemoradiotherapy for locoregionally advanced salivary gland malignancies.
Rosenberg L; Weissler M; Hayes DN; Shockley W; Zanation A; Rosenman J; Chera B
Head Neck; 2012 Jun; 34(6):872-6. PubMed ID: 22127998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
